Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $5.4 million.

  • Lipocine's Shares Outstanding (Diluted Average) rose 121.93% to $5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 million, marking a year-over-year increase of 121.93%. This contributed to the annual value of $5.4 million for FY2024, which is 290.21% up from last year.
  • Per Lipocine's latest filing, its Shares Outstanding (Diluted Average) stood at $5.4 million for Q3 2025, which was up 121.93% from $5.4 million recorded in Q2 2025.
  • In the past 5 years, Lipocine's Shares Outstanding (Diluted Average) ranged from a high of $89.0 million in Q2 2021 and a low of $5.2 million during Q1 2023
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $5.4 million (2025), whereas its average is $26.9 million.
  • Per our database at Business Quant, Lipocine's Shares Outstanding (Diluted Average) soared by 9803.16% in 2021 and then plummeted by 9408.69% in 2022.
  • Quarter analysis of 5 years shows Lipocine's Shares Outstanding (Diluted Average) stood at $87.6 million in 2021, then tumbled by 94.0% to $5.3 million in 2022, then rose by 0.26% to $5.3 million in 2023, then rose by 2.9% to $5.4 million in 2024, then decreased by 0.17% to $5.4 million in 2025.
  • Its last three reported values are $5.4 million in Q3 2025, $5.4 million for Q2 2025, and $5.3 million during Q1 2025.